The Park Sleep subtype in Parkinson’s disease: from concept to clinic

References

• Todorova A, Jenner P, Ray Chaudhuri K. Non-motor Parkinson’s: integral to motor Parkinson’s, yet often neglected. Pract Neurol. 2014 Oct;14(5):310–322. doi: 10.1136/practneurol-2013-000741
   PubMedGoogle Scholar
• Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, et al. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Mov Disord. 2011 Feb 15;26(3):399–406. doi: 10.1002/mds.23462
   PubMed Web of Science ®Google Scholar
• Politis M, Wu K, Molloy S, et al. Parkinson’s disease symptoms: the patient’s perspective. Mov Disord. 2010 Aug 15;25(11):1646–1651. doi: 10.1002/mds.23135
   PubMed Web of Science ®Google Scholar
• Sauerbier A, Jenner P, Todorova A, et al. Non motor subtypes and Parkinson’s disease. Parkinsonism Related Disord. 2016 /Jan/1/;22:S41–S46. doi: 10.1016/j.parkreldis.2015.09.027
   PubMed Web of Science ®Google Scholar
• Marras C, Chaudhuri KR. Nonmotor features of Parkinson’s disease subtypes. Mov Disord. 2016 Aug;31(8):1095–1102. doi: 10.1002/mds.26510
   PubMed Web of Science ®Google Scholar
• Titova N, Chaudhuri KR. Personalized medicine in Parkinson’s disease: time to be precise. Mov Disord. 2017 Aug;32(8):1147–1154. doi: 10.1002/mds.27027
   PubMed Web of Science ®Google Scholar
• Titova N, Chaudhuri KR. Non-motor Parkinson disease: new concepts and personalised management. Med J Aust. 2018 May 21;208(9):404–409. doi: 10.5694/mja17.00993
   PubMed Web of Science ®Google Scholar
• Rodriguez-Sanchez F, Rodriguez-Blazquez C, Bielza C, et al. Identifying Parkinson’s disease subtypes with motor and non-motor symptoms via model-based multi-partition clustering. Sci Rep. 2021 Dec 8;11(1):23645. doi: 10.1038/s41598-021-03118-w
   PubMed Web of Science ®Google Scholar
• Erro R, Vitale C, Amboni M, et al. The heterogeneity of early Parkinson’s disease: a cluster analysis on newly diagnosed untreated patients. PLoS One. 2013;8(8):e70244. doi: 10.1371/journal.pone.0070244
   PubMed Web of Science ®Google Scholar
• Wasserman D, Bindman D, Nesbitt AD, et al. Striatal dopaminergic deficit and sleep in idiopathic rapid eye movement behaviour disorder: an explorative study. Nat Sci Sleep. 2021;13:1–9. DOI:10.2147/NSS.S267037
   PubMed Web of Science ®Google Scholar
• Mantovani S, Smith SS, Gordon R, et al. An overview of sleep and circadian dysfunction in Parkinson’s disease. J Sleep Res. 2018 Jun;27(3):e12673. doi: 10.1111/jsr.12673
   PubMed Web of Science ®Google Scholar
• Stefani A, Högl B. Sleep in Parkinson’s disease. Neuropsychopharmacology. 2020 Jan;45(1):121–128. doi: 10.1038/s41386-019-0448-y
   PubMed Web of Science ®Google Scholar
• Hunt J, Coulson EJ, Rajnarayanan R, et al. Sleep and circadian rhythms in Parkinson’s disease and preclinical models. Mol Neurodegener. 2022 Jan 9;17(1):2. doi: 10.1186/s13024-021-00504-w
   PubMed Web of Science ®Google Scholar
• Trenkwalder C. Sleep dysfunction in Parkinson’s disease. Clin Neurosci. 1998;5(2):107–114.
   PubMedGoogle Scholar
• Mu J, Chaudhuri KR, Bielza C, et al. Parkinson’s Disease subtypes identified from cluster analysis of motor and non-motor symptoms. Front Aging Neurosci. 2017;9:301. doi: 10.3389/fnagi.2017.00301
   PubMed Web of Science ®Google Scholar
• Keir LHM, Breen DP. New awakenings: current understanding of sleep dysfunction and its treatment in Parkinson’s disease. J Neurol. 2020 Jan;267(1):288–294. doi: 10.1007/s00415-019-09651-z
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Leta V, Bannister K, et al. The noradrenergic subtype of Parkinson disease: from animal models to clinical practice. Nat Rev Neurol. 2023 Jun;19(6):333–345. doi: 10.1038/s41582-023-00802-5
   PubMed Web of Science ®Google Scholar
• Pérez-Carbonell L, Mignot E, Leschziner G, et al. Understanding and approaching excessive daytime sleepiness. Lancet. 2022 Sep 24;400(10357):1033–1046. doi: 10.1016/S0140-6736(22)01018-2
   PubMed Web of Science ®Google Scholar
• Abbott RD, Ross G, White L, et al. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology. 2005;65(9):1442–1446. doi: 10.1212/01.wnl.0000183056.89590.0d
   PubMed Web of Science ®Google Scholar
• Diederich NJ, Vaillant M, Mancuso G, et al. Progressive sleep ‘destructuring’in Parkinson’s disease. A polysomnographic study in 46 patients. Sleep Med. 2005;6(4):313–318. doi: 10.1016/j.sleep.2005.03.011
   PubMed Web of Science ®Google Scholar
• O’Suilleabhain PE, Dewey, Jr RB Jr. Contributions of dopaminergic drugs and disease severity to daytime sleepiness in Parkinson disease. Arch Neurol. 2002;59(6):986–989. doi: 10.1001/archneur.59.6.986
   PubMedGoogle Scholar
• Kumar S, Bhatia M, Behari M. Excessive daytime sleepiness in Parkinson’s disease as assessed by Epworth Sleepiness Scale (ESS). Sleep Med. 2003;4(4):339–342. doi: 10.1016/S1389-9457(03)00105-9
   PubMed Web of Science ®Google Scholar
• Pal S, Bhattacharya K, Agapito C, et al. A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson’s disease patients taking pramipexole, cabergoline and levodopa mono and combination therapy. J Neural Transm. 2001;108(1):71–77. doi: 10.1007/s007020170098
   PubMed Web of Science ®Google Scholar
• Boeve BF. REM sleep behavior disorder: updated review of the core features, the REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions. Ann N Y Acad Sci. 2010 Jan;1184(1):15–54. doi: 10.1111/j.1749-6632.2009.05115.x
   PubMed Web of Science ®Google Scholar
• Zhang X, Sun X, Wang J, et al. Prevalence of rapid eye movement sleep behavior disorder (RBD) in Parkinson’s disease: a meta and meta-regression analysis. Neurol Sci. 2017;38(1):163–170. doi: 10.1007/s10072-016-2744-1
   PubMed Web of Science ®Google Scholar
• Högl B, Stefani A, Videnovic A. Idiopathic REM sleep behaviour disorder and neurodegeneration—an update. Nat Rev Neurol. 2018;14(1):40–55. doi: 10.1038/nrneurol.2017.157
   PubMed Web of Science ®Google Scholar
• Arnaldi D, Antelmi E, Louis EKS, et al. Idiopathic REM sleep behavior disorder and neurodegenerative risk: to tell or not to tell to the patient? How to minimize the risk? Sleep Med Rev. 2017;36:82–95. DOI:10.1016/j.smrv.2016.11.002
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Leta V, Bannister K, et al. The noradrenergic subtype of Parkinson’s disease. Nat Rev Neurol. 2023;19:333–345.
   PubMed Web of Science ®Google Scholar
• American psychiatric association D, association AP. Diagnostic and statistical manual of mental disorders: DSM-5.American Psychiatric Association.2013;5:5. Washington, DC: American Psychiatric Association.
   Google Scholar
• Gros P, Videnovic A. Sleep and circadian rhythm disorders in Parkinson’s disease. Curr Sleep Medicine Rep. 2017;3(3):222–234. doi: 10.1007/s40675-017-0079-y
   PubMedGoogle Scholar
• Zhu K, van Hilten JJ, Marinus J, et al. The course of insomnia in Parkinson’s disease. Parkinsonism Related Disord. 2016;33:51–57. doi: 10.1016/j.parkreldis.2016.09.010
   PubMed Web of Science ®Google Scholar
• Kay DB, Tanner JJ, Bowers D. Sleep disturbances and depression severity in patients with Parkinson’s disease. Brain Behav. 2018;8(6):e00967. doi: 10.1002/brb3.967
   PubMed Web of Science ®Google Scholar
• Crosta F, Desideri G, Marini C. Obstructive sleep apnea syndrome in Parkinson’s disease and other parkinsonisms. Funct Neurol. 2017;32(3):137. doi: 10.11138/FNeur/2017.32.3.137
   PubMed Web of Science ®Google Scholar
• Malhotra A, White DP. Obstructive sleep apnoea. Lancet. 2002;360(9328):237–245. doi: 10.1016/S0140-6736(02)09464-3
   PubMed Web of Science ®Google Scholar
• Kaminska M, Lafontaine AL, Kimoff RJ. The interaction between obstructive sleep apnea and parkinson’s disease: possible mechanisms and implications for cognitive function. Parkinsons Dis. 2015;2015:1–11. doi: 10.1155/2015/849472
   Web of Science ®Google Scholar
• Redline S, Kapur VK, Sanders MH, et al. Effects of varying approaches for identifying respiratory disturbances on sleep apnea assessment. Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):369–374. doi: 10.1164/ajrccm.161.2.9904031
   PubMed Web of Science ®Google Scholar
• Sobreira-Neto MA, Pena-Pereira MA, Sobreira EST, et al. Obstructive sleep apnea and Parkinson’s disease: characteristics and associated factors. Arq Neuropsiquiatr. 2019;77(9):609–616. doi: 10.1590/0004-282x20190098
   PubMed Web of Science ®Google Scholar
• Schulte EC, Winkelmann J. When Parkinson’s disease patients go to sleep: specific sleep disturbances related to Parkinson’s disease.J Neurol. 2011 [2011/May/1];258(2):328–335. DOI:10.1007/s00415-011-5933-0.
   PubMedGoogle Scholar
• Andrade AG, Bubu OM, Varga AW, et al. The relationship between obstructive sleep apnea and Alzheimer’s disease. J Alzheimers Dis. 2018;64(s1):S255–S270. doi: 10.3233/JAD-179936
   PubMed Web of Science ®Google Scholar
• Reitz C, Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol. 2014;88(4):640–651. doi: 10.1016/j.bcp.2013.12.024
   PubMed Web of Science ®Google Scholar
• Bucks RS, Olaithe M, Rosenzweig I, et al. Reviewing the relationship between OSA and cognition: where do we go from here? Respirology. 2017;22(7):1253–1261. doi: 10.1111/resp.13140
   PubMed Web of Science ®Google Scholar
• Zhang X, Molsberry SA, Pavlova M, et al. Association of sleepwalking and REM sleep behavior disorder with Parkinson disease in men. JAMA Netw Open. 2021 Apr 1;4(4):e215713. doi: 10.1001/jamanetworkopen.2021.5713
   PubMed Web of Science ®Google Scholar
• Terzaghi M, Minafra B, Zangaglia R, et al. NREM sleep arousal-related disorders reflect cognitive impairment in Parkinson’s disease. Sleep Med. 2020 [2020/Nov/1/];75:491–496.
   PubMed Web of Science ®Google Scholar
• Messina A, Bitetti I, Precenzano F, et al. Non-Rapid eye movement sleep parasomnias and migraine: a role of orexinergic projections [hypothesis and theory]. Front Neurol. 2018 [2018-Feb-28];9. doi: 10.3389/fneur.2018.00095
   PubMed Web of Science ®Google Scholar
• Juszczak GR, Swiergiel AH Serotonergic hypothesis of sleepwalking. Med Hypotheses. 2005;64(1):28–32. 2005/01/01/. doi: 10.1016/j.mehy.2004.06.013
   PubMed Web of Science ®Google Scholar
• Endo T, Matsumura R, Tokuda IT, et al. Bright light improves sleep in patients with Parkinson’s disease: possible role of circadian restoration. Sci Rep. 2020;10(1):7982. 2020/05/14. doi: 10.1038/s41598-020-64645-6
   PubMed Web of Science ®Google Scholar
• Breen DP, Vuono R, Nawarathna U, et al. Sleep and circadian rhythm regulation in early Parkinson disease. JAMA Neurol. 2014 May;71(5):589–595. doi: 10.1001/jamaneurol.2014.65
   PubMed Web of Science ®Google Scholar
• Coomans CP, Ramkisoensing A, Meijer JH. The suprachiasmatic nuclei as a seasonal clock. Front Neuroendocrinol. 2015 Apr;37:29–42. doi: 10.1016/j.yfrne.2014.11.002
   PubMed Web of Science ®Google Scholar
• La Morgia C, Ross-Cisneros FN, Sadun AA, et al. Retinal ganglion cells and circadian rhythms in alzheimer’s disease, parkinson’s disease, and beyond. Front Neurol. 2017;8:162. doi: 10.3389/fneur.2017.00162
   PubMed Web of Science ®Google Scholar
• Högl B, Stefani A. REM sleep behavior disorder (RBD): update on diagnosis and treatment. Somnologie (Berl). 2017;21(Suppl 1):1–8. doi: 10.1007/s11818-016-0048-6
   PubMedGoogle Scholar
• Cesari M, Heidbreder A, St Louis EK, et al. Video-polysomnography procedures for diagnosis of rapid eye movement sleep behavior disorder (RBD) and the identification of its prodromal stages: guidelines from the International RBD study group. Sleep. 2022 Mar 14;45(3). doi: 10.1093/sleep/zsab257
   PubMed Web of Science ®Google Scholar
• Otaiku AI Association of sleep abnormalities in older adults with risk of developing Parkinson’s disease. Sleep. 2022 Nov 9;45(11). doi: 10.1093/sleep/zsac206
   PubMed Web of Science ®Google Scholar
• Cesari M, Christensen JAE, Muntean ML, et al. A data-driven system to identify REM sleep behavior disorder and to predict its progression from the prodromal stage in Parkinson’s disease. Sleep Med. 2021 Jan;77:238–248.
   PubMed Web of Science ®Google Scholar
• Chahine LM, Kauta SR, Daley JT, et al. Surface EMG activity during REM sleep in Parkinson’s disease correlates with disease severity. Parkinsonism Relat Disord. 2014 Jul;20(7):766–771. doi: 10.1016/j.parkreldis.2014.04.011
   PubMed Web of Science ®Google Scholar
• Dijkstra F, de Volder I, Viaene M, et al. Polysomnographic predictors of sleep, motor, and cognitive dysfunction progression in Parkinson’s disease. Curr Neurol Neurosci Rep. 2022 Oct;22(10):657–674. doi: 10.1007/s11910-022-01226-2
   PubMed Web of Science ®Google Scholar
• Skorvanek M, Feketeova E, Kurtis MM, et al. Accuracy of rating scales and clinical measures for screening of rapid eye movement sleep behavior disorder and for predicting conversion to Parkinson’s disease and other synucleinopathies [review]. Front Neurol. 2018 [2018-May-25];9. doi: 10.3389/fneur.2018.00376
   PubMed Web of Science ®Google Scholar
• Rodrigues Brazète J, Gagnon JF, Postuma RB, et al. Electroencephalogram slowing predicts neurodegeneration in rapid eye movement sleep behavior disorder. Neurobiol Aging. 2016 Jan;37:74–81.
   PubMed Web of Science ®Google Scholar
• Ferini-Strambi L, Fasiello E, Sforza M, et al. Neuropsychological, electrophysiological, and neuroimaging biomarkers for REM behavior disorder. Expert Rev Neurother. 2019 Nov;19(11):1069–1087. doi: 10.1080/14737175.2019.1640603
   PubMed Web of Science ®Google Scholar
• Li Y, Kang W, Yang Q, et al. Predictive markers for early conversion of iRBD to neurodegenerative synucleinopathy diseases. Neurology. 2017 Apr 18;88(16):1493–1500. doi: 10.1212/WNL.0000000000003838
   PubMed Web of Science ®Google Scholar
• Iranzo A, Santamaría J, Valldeoriola F, et al. Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder. Ann Neurol. 2017 Sep;82(3):419–428. doi: 10.1002/ana.25026
   PubMed Web of Science ®Google Scholar
• Iranzo A, Valldeoriola F, Lomeña F, et al. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol. 2011 Sep;10(9):797–805. doi: 10.1016/S1474-4422(11)70152-1
   PubMed Web of Science ®Google Scholar
• Happe S, Baier PC, Helmschmied K, et al. Association of daytime sleepiness with nigrostriatal dopaminergic degeneration in early Parkinson’s disease. J Neurol. 2007 Aug;254(8):1037–1043. doi: 10.1007/s00415-006-0483-6
   PubMed Web of Science ®Google Scholar
• Yousaf T, Pagano G, Niccolini F, et al. Excessive daytime sleepiness may be associated with caudate denervation in Parkinson disease. J Neurol Sci. 2018 Apr 15;387:220–227. doi: 10.1016/j.jns.2018.02.032
   PubMed Web of Science ®Google Scholar
• Eisensehr I, Linke R, Tatsch K, et al. Alteration of the striatal dopaminergic system in human narcolepsy. Neurology. 2003 Jun 10;60(11):1817–1819. doi: 10.1212/01.WNL.0000069608.84542.46
   PubMed Web of Science ®Google Scholar
• Ge J, Wu P, Peng S, et al. Assessing cerebral glucose metabolism in patients with idiopathic rapid eye movement sleep behavior disorder. J Cereb Blood Flow Metab. 2015;35(12):2062–2069. doi: 10.1038/jcbfm.2015.173
   PubMed Web of Science ®Google Scholar
• Liguori C, Ruffini R, Olivola E, et al. Cerebral glucose metabolism in idiopathic REM sleep behavior disorder is different from tau-related and α-synuclein-related neurodegenerative disorders: A brain [18F]FDG PET study. Parkinsonism Relat Disord. 2019 Jul;64:97–105.
   PubMed Web of Science ®Google Scholar
• Diaz-Galvan P, Miyagawa T, Przybelski SA, et al. Brain glucose metabolism and nigrostriatal degeneration in isolated rapid eye movement sleep behaviour disorder. Brain Commun. 2023;5(1):fcad021. doi: 10.1093/braincomms/fcad021
   PubMedGoogle Scholar
• Yang C, Chang J, Liang X, et al. Gray matter alterations in parkinson’s disease with rapid eye movement sleep behavior disorder: a meta-analysis of voxel-based morphometry studies. Front Aging Neurosci. 2020;12:213. doi: 10.3389/fnagi.2020.00213
   PubMed Web of Science ®Google Scholar
• Rahayel S, Gaubert M, Postuma RB, et al. Brain atrophy in Parkinson’s disease with polysomnography-confirmed REM sleep behavior disorder. Sleep. 2019 Jun 11;42(6). doi: 10.1093/sleep/zsz062
   PubMed Web of Science ®Google Scholar
• Salsone M, Cerasa A, Arabia G, et al. Reduced thalamic volume in Parkinson disease with REM sleep behavior disorder: volumetric study. Parkinsonism Relat Disord. 2014 Sep;20(9):1004–1008. doi: 10.1016/j.parkreldis.2014.06.012
   PubMed Web of Science ®Google Scholar
• Jiang X, Wu Z, Zhong M, et al. Abnormal gray matter volume and functional connectivity in parkinson’s disease with rapid eye movement sleep behavior disorder. Parkinsons Dis. 2021;2021:8851027. doi: 10.1155/2021/8851027
   PubMed Web of Science ®Google Scholar
• Pyatigorskaya N, Gaurav R, Arnaldi D, et al. Magnetic resonance imaging biomarkers to assess substantia nigra damage in idiopathic rapid eye movement sleep behavior disorder. Sleep. 2017 Nov 1;40(11). doi: 10.1093/sleep/zsx149
   PubMed Web of Science ®Google Scholar
• Sommerauer M, Fedorova TD, Hansen AK, et al. Evaluation of the noradrenergic system in Parkinson’s disease: an 11C-MeNER PET and neuromelanin MRI study. Brain. 2018 Feb 1;141(2):496–504. doi: 10.1093/brain/awx348
   PubMedGoogle Scholar
• Wilson H, Giordano B, Turkheimer FE, et al. Serotonergic dysregulation is linked to sleep problems in Parkinson’s disease. NeuroImage Clin. 2018;18:630–637. doi: 10.1016/j.nicl.2018.03.001
   PubMed Web of Science ®Google Scholar
• Mizrahi-Kliger AD, Feldmann LK, Kühn AA, et al. Etiologies of insomnia in Parkinson’s disease – lessons from human studies and animal models. Exp Neurol [ 2022/04/01/]. 2022;350:113976. doi: 10.1016/j.expneurol.2022.113976
   PubMed Web of Science ®Google Scholar
• Prieto GA. Abnormalities of Dopamine D(3) receptor signaling in the diseased brain. J Cent Nerv Syst Dis. 2017;9:1179573517726335. doi: 10.1177/1179573517726335
   Google Scholar
• Yang P, Perlmutter JS, Benzinger TLS, et al. Dopamine D3 receptor: A neglected participant in Parkinson disease pathogenesis and treatment? Ageing Res Rev. 2020 Jan;57:100994.
   PubMed Web of Science ®Google Scholar
• Janzen A, Vadasz D, Booij J, et al. Progressive olfactory impairment and cardiac sympathetic denervation in REM sleep behavior disorder. J Parkinsons Dis. 2022;12(6):1921–1935. doi: 10.3233/JPD-223201
   PubMedGoogle Scholar
• Knudsen K, Fedorova TD, Hansen AK, et al. In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study. Lancet Neurol. 2018 Jul;17(7):618–628. doi: 10.1016/S1474-4422(18)30162-5
   PubMed Web of Science ®Google Scholar
• Fernández-Santiago R, Iranzo A, Gaig C, et al. MicroRNA association with synucleinopathy conversion in rapid eye movement behavior disorder. Ann Neurol. 2015 May;77(5):895–901. doi: 10.1002/ana.24384
   PubMed Web of Science ®Google Scholar
• Ferrie JE, Kivimäki M, Akbaraly TN, et al. Associations between change in sleep duration and inflammation: findings on C-reactive protein and interleukin 6 in the Whitehall II study. Am J Epidemiol. 2013 Sep 15;178(6):956–961. doi: 10.1093/aje/kwt072
   PubMed Web of Science ®Google Scholar
• Li L, Zhao Z, Ma J, et al. Elevated plasma melatonin levels are correlated with the non-motor symptoms in parkinson’s disease: a cross-sectional study [original research]. Front Neurosci. 2020 [2020-May-19];14:14.
   PubMed Web of Science ®Google Scholar
• Videnovic A, Noble C, Reid KJ, et al. Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease. JAMA Neurol. 2014;71(4):463–469. doi: 10.1001/jamaneurol.2013.6239
   PubMed Web of Science ®Google Scholar
• Rossi M, Candelise N, Baiardi S, et al. Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. Acta Neuropathol. 2020;140(1):49–62. doi: 10.1007/s00401-020-02160-8
   PubMed Web of Science ®Google Scholar
• Iranzo A, Fairfoul G, Ayudhaya ACN, et al. Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study. Lancet Neurol. 2021;20(3):203–212. doi: 10.1016/S1474-4422(20)30449-X
   PubMed Web of Science ®Google Scholar
• Wang X-T, Liu F-T, Bi Y-L, et al. Associations of sleep characteristics with alpha-synuclein in cerebrospinal fluid in older adults. Ann Clin Transl Neurol. 2020;7(10):2026–2034. doi: 10.1002/acn3.51204
   PubMed Web of Science ®Google Scholar
• Wang X-T, Yu H, Liu F-T, et al. Associations of sleep disorders with cerebrospinal fluid α-synuclein in prodromal and early Parkinson’s disease. J Neurol. 2022;269(5):2469–2478. 2022/05/01. doi: 10.1007/s00415-021-10812-2
   PubMed Web of Science ®Google Scholar
• Ripley B, Overeem S, Fujiki N, et al. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology. 2001;57(12):2253–2258. doi: 10.1212/WNL.57.12.2253
   PubMed Web of Science ®Google Scholar
• Drouot X, Moutereau S, Nguyen J, et al. Low levels of ventricular CSF orexin/hypocretin in advanced PD. Neurology. 2003;61(4):540–543. doi: 10.1212/01.WNL.0000078194.53210.48
   PubMed Web of Science ®Google Scholar
• Overeem S, Van Hilten J, Ripley B, et al. Normal hypocretin-1 levels in Parkinson’s disease patients with excessive daytime sleepiness. Neurology. 2002;58(3):498–499. doi: 10.1212/WNL.58.3.498
   PubMed Web of Science ®Google Scholar
• Yasui K, Inoue Y, Kanbayashi T, et al. CSF orexin levels of Parkinson’s disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration. J Neurolog Sci. 2006;250(1):120–123. 2006/12/01/. doi: 10.1016/j.jns.2006.08.004
   PubMed Web of Science ®Google Scholar
• Ogawa T, Kajiyama Y, Ishido H, et al. Decreased cerebrospinal fluid orexin levels not associated with clinical sleep disturbance in Parkinson’s disease: A retrospective study. PLoS One. 2022;17(12):e0279747. doi: 10.1371/journal.pone.0279747
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Kanbayashi T, Hoshikawa M, et al. Relationship of orexin (hypocretin) system and astrocyte activation in Parkinson’s disease with hypersomnolence. Sleep Biol Rhythms. 2015;13(3):252–260. doi: 10.1111/sbr.12112
   Web of Science ®Google Scholar
• Li M, Wang L, Liu JH, et al. Relationships between rapid eye movement sleep behavior disorder and neurodegenerative diseases: clinical assessments, biomarkers, and treatment. Chin Med J (Engl). 2018 Apr 20;131(8):966–973. doi: 10.4103/0366-6999.229886
   PubMed Web of Science ®Google Scholar
• Bjørnarå KA, Pihlstrøm L, Dietrichs E, et al. Risk variants of the α-synuclein locus and REM sleep behavior disorder in Parkinson’s disease: a genetic association study. BMC neurol. 2018;18(1):1–5. doi: 10.1186/s12883-018-1023-6
   PubMedGoogle Scholar
• Toffoli M, Dreussi E, Cecchin E, et al. SNCA 3′ UTR genetic variants in patients with Parkinson’s disease and REM sleep behavior disorder. Neurol Sci. 2017;38(7):1233–1240. doi: 10.1007/s10072-017-2945-2
   PubMed Web of Science ®Google Scholar
• Pont-Sunyer C, Iranzo A, Gaig C, et al. Sleep disorders in parkinsonian and nonparkinsonian LRRK2 mutation carriers. PLoS One. 2015;10(7):e0132368. doi: 10.1371/journal.pone.0132368
   PubMed Web of Science ®Google Scholar
• Pont-Sunyer C, Tolosa E, Caspell-Garcia C, et al. The prodromal phase of leucine-rich repeat kinase 2-associated Parkinson disease: clinical and imaging studies. Mov Disord. 2017 May;32(5):726–738. doi: 10.1002/mds.26964
   PubMed Web of Science ®Google Scholar
• Limousin N, Konofal E, Karroum E, et al. Restless legs syndrome, rapid eye movement sleep behavior disorder, and hypersomnia in patients with two parkin mutations. Mov Disord. 2009 Oct 15;24(13):1970–1976. doi: 10.1002/mds.22711
   PubMed Web of Science ®Google Scholar
• Wang H, Lane JM, Jones SE, et al. Genome-wide association analysis of self-reported daytime sleepiness identifies 42 loci that suggest biological subtypes. Nat Commun. 2019;10(1):3503. 2019/08/13. doi: 10.1038/s41467-019-11456-7
   PubMed Web of Science ®Google Scholar
• Nuzum ND, Loughman A, Szymlek-Gay EA, et al. To the gut microbiome and beyond: the brain-first or body-first hypothesis in Parkinson’s disease. Front Microbiol. 2022;13:791213. doi: 10.3389/fmicb.2022.791213
   PubMed Web of Science ®Google Scholar
• Heintz‐Buschart A, Pandey U, Wicke T, et al. The nasal and gut microbiome in Parkinson’s disease and idiopathic rapid eye movement sleep behavior disorder. Mov Disord. 2018;33(1):88–98. doi: 10.1002/mds.27105
   PubMed Web of Science ®Google Scholar
• Postuma RB, Iranzo A, Hu M, et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain. 2019 Mar 1;142(3):744–759. doi: 10.1093/brain/awz030
   PubMedGoogle Scholar
• Aurora RN, Zak RS, Maganti RK, et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med. 2010 Feb 15;6(1):85–95. doi: 10.5664/jcsm.27717
   PubMed Web of Science ®Google Scholar
• Haq IZ, Naidu Y, Reddy P, et al. Narcolepsy in Parkinson’s disease. Expert Rev Neurotherapeutics. 2010;10(6):879–884. 2010/06/01. doi: 10.1586/ern.10.56
   PubMed Web of Science ®Google Scholar
• Frucht S, Rogers JD, Greene PE, et al. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology. 1999 Jun 10;52(9):1908–1910. doi: 10.1212/WNL.52.9.1908
   PubMed Web of Science ®Google Scholar
• Marras C, Chaudhuri KR, Titova N, et al. Therapy of Parkinson’s disease subtypes. Neurotherapeutics. 2020 Oct;17(4):1366–1377. doi: 10.1007/s13311-020-00894-7
   PubMed Web of Science ®Google Scholar
• Neutel D, Peralta R, Pires J, et al. End of OSLER test sessions in Parkinson’s disease do not correspond to true sleep onset: results from an exploratory study [original research]. Front Neurol. 2015 [2015-Sep-24];6:6.
   PubMed Web of Science ®Google Scholar
• BENNETT L, STRADLING J, DAVIES R. A behavioural test to assess daytime sleepiness in obstructive sleep apnoea. J Sleep Res. 1997;6(2):142–145. doi: 10.1046/j.1365-2869.1997.00039.x
   PubMed Web of Science ®Google Scholar
• Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson’s disease-an evidence-based medicine review. Mov Disord. 2019 Feb;34(2):180–198. doi: 10.1002/mds.27602
   PubMed Web of Science ®Google Scholar
• Adler CH, Caviness JN, Hentz JG, et al. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson’s disease. Mov Disord. 2003;18(3):287–293. doi: 10.1002/mds.10390
   PubMed Web of Science ®Google Scholar
• Högl B, Saletu M, Brandauer E, et al. Modafinil for the treatment of daytime sleepiness in Parkinson’s disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep. 2002 Dec;25(8):905–909. doi: 10.1093/sleep/25.8.62
   PubMed Web of Science ®Google Scholar
• Ondo WG, Fayle R, Atassi F, et al. Modafinil for daytime somnolence in Parkinson’s disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry. 2005 Dec;76(12):1636–1639. doi: 10.1136/jnnp.2005.065870
   PubMed Web of Science ®Google Scholar
• Rodrigues TM, Castro Caldas A, Ferreira JJ. Pharmacological interventions for daytime sleepiness and sleep disorders in Parkinson’s disease: systematic review and meta-analysis. Parkinsonism Relat Disord. 2016 Jun;27:25–34. doi: 10.1016/j.parkreldis.2016.03.002
   PubMed Web of Science ®Google Scholar
• Knie B, Mitra MT, Logishetty K, et al. Excessive daytime sleepiness in patients with Parkinson’s disease. CNS Drugs. 2011 Mar;25(3):203–212. doi: 10.2165/11539720-000000000-00000
   PubMed Web of Science ®Google Scholar
• Ando R, Choudhury ME, Yamanishi Y, et al. Modafinil alleviates levodopa-induced excessive nighttime sleepiness and restores monoaminergic systems in a nocturnal animal model of Parkinson’s disease. J Pharmacol Sci. 2018;136(4):266–271. 2018/04/01/. doi: 10.1016/j.jphs.2018.03.005
   PubMed Web of Science ®Google Scholar
• Van Vliet SA, Vanwersch RA, Jongsma MJ, et al. Neuroprotective effects of modafinil in a marmoset Parkinson model: behavioral and neurochemical aspects. Behav Pharmacol. 2006;17(5–6):453–462. doi: 10.1097/00008877-200609000-00011
   PubMed Web of Science ®Google Scholar
• Jenner P, Zeng B-Y, Smith L, et al. Antiparkinsonian and neuroprotective effects of modafinil in the mptp-treated common marmoset. Exp Brain Res. 2000;133(2):178–188. doi: 10.1007/s002210000370
   PubMed Web of Science ®Google Scholar
• Aguirre J, Cintra A, Hillion J, et al. A stereological study on the neuroprotective actions of acute modafinil treatment on 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced nigral lesions of the male black mouse. Neurosci lett. 1999;275(3):215–218. doi: 10.1016/S0304-3940(99)00706-5
   PubMed Web of Science ®Google Scholar
• Hu X, Li J, Wang X, et al. Neuroprotective Effect of Melatonin on Sleep Disorders Associated with Parkinson’s Disease. Antioxidants. 2023;12(2):396. doi: 10.3390/antiox12020396
   Web of Science ®Google Scholar
• Liguori C, Placidi F, Izzi F, et al. Pitolisant for treating narcolepsy comorbid with Parkinson’s disease. Sleep Med [ 2020/05/01/]. 2020;69:86–87. doi: 10.1016/j.sleep.2020.01.020
   PubMed Web of Science ®Google Scholar
• Yang J, Gao J. Solriamfetol for the treatment of excessive daytime sleepiness associated with narcolepsy. Expert Rev Clin Pharmacol. 2019 Aug;12(8):723–728. doi: 10.1080/17512433.2019.1632705
   PubMed Web of Science ®Google Scholar
• Videnovic A, Amara AW, Comella C, et al. Solriamfetol for excessive daytime sleepiness in parkinson’s disease: phase 2 proof-of-concept trial. Mov Disord. 2021;36(10):2408–2412. doi: 10.1002/mds.28702
   PubMed Web of Science ®Google Scholar
• Iturburu A, Pallares Vela E, Cruz C, et al. Solriamfetol for the use of narcolepsy: a systematic review. Cureus. 2022 May;14(5):e24937. doi: 10.7759/cureus.24937
   PubMedGoogle Scholar
• Muehlan C, Vaillant C, Zenklusen I, et al. Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders. Expert Opin Drug Metab Toxicol. 2020 Nov;16(11):1063–1078. doi: 10.1080/17425255.2020.1817380
   PubMed Web of Science ®Google Scholar
• Cheng JY, Filippov G, Moline M, et al. Respiratory safety of lemborexant in healthy adult and elderly subjects with mild obstructive sleep apnea: A randomized, double-blind, placebo-controlled, crossover study. J Sleep Res. 2020 Aug;29(4):e13021. doi: 10.1111/jsr.13021
   PubMed Web of Science ®Google Scholar
• Moline M, Zammit G, Yardley J, et al. Lack of residual morning effects of lemborexant treatment for insomnia: summary of findings across 9 clinical trials. Postgrad Med. 2021 Jan;133(1):71–81. doi: 10.1080/00325481.2020.1823724
   PubMed Web of Science ®Google Scholar
• Meng L, Benedetti A, Lafontaine AL, et al. Obstructive sleep apnea, CPAP therapy and Parkinson’s disease motor function: A longitudinal study. Parkinsonism Relat Disord. 2020 Jan;70:45–50.
   PubMed Web of Science ®Google Scholar
• Neikrug AB, Liu L, Avanzino JA, et al. Continuous positive airway pressure improves sleep and daytime sleepiness in patients with Parkinson disease and sleep apnea. Sleep. 2014 Jan 1;37(1):177–185. doi: 10.5665/sleep.3332
   PubMed Web of Science ®Google Scholar
• Ou R, Hou Y, Wei Q, et al. Longitudinal evolution of non-motor symptoms in early Parkinson’s disease: a 3-year prospective cohort study. NPJ Parkinsons Dis. 2021 Jul 15;7(1):58. doi: 10.1038/s41531-021-00207-5
   PubMed Web of Science ®Google Scholar
• Santos-García D, de Deus T, Cores C, et al. Predictors of global non-motor symptoms burden progression in Parkinson’s disease. Results from the COPPADIS cohort at 2-year follow-up. J Pers Med. 2021 Jun 30;11(7):626. doi: 10.3390/jpm11070626
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Antonini A, Pahwa R, et al. Effects of levodopa-carbidopa intestinal gel on dyskinesia and non-motor symptoms including sleep: results from a meta-analysis with 24-month follow-up. J Parkinsons Dis. 2022;12(7):2071–2083. doi: 10.3233/JPD-223295
   PubMedGoogle Scholar
• Antonini A, Poewe W, Chaudhuri KR, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson’s: final results of the GLORIA registry. Parkinsonism Relat Disord. 2017 Dec;45:13–20.
   PubMed Web of Science ®Google Scholar
• Standaert DG, Aldred J, Anca-Herschkovitsch M, et al. DUOGLOBE: one-year outcomes in a real-world study of levodopa carbidopa intestinal gel for Parkinson’s disease. Mov Disord Clin Pract. 2021 Oct;8(7):1061–1074. doi: 10.1002/mdc3.13239
   PubMed Web of Science ®Google Scholar
• De Cock VC, Dodet P, Leu-Semenescu S, et al. Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson’s disease (APOMORPHEE): a multicentre, randomised, controlled, double-blind crossover study. Lancet Neurol. 2022 May;21(5):428–437. doi: 10.1016/S1474-4422(22)00085-0
   PubMed Web of Science ®Google Scholar
• Högl B, Oertel WH, Stiasny-Kolster K, et al. Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch. BMC neurol. 2010 Sep 28;10(1):86. doi: 10.1186/1471-2377-10-86
   PubMedGoogle Scholar
• Oertel W, Trenkwalder C, Beneš H, et al. Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet Neurol. 2011 Aug;10(8):710–720. doi: 10.1016/S1474-4422(11)70127-2
   PubMed Web of Science ®Google Scholar
• Lee J, Kim Y, Kim YL. Non-pharmacological therapies for sleep disturbances in people with Parkinson’s disease: A systematic review. J Adv Nurs. 2018 Apr 27;74(8):1741–1751. doi: 10.1111/jan.13694
   Web of Science ®Google Scholar
• Taximaimaiti R, Luo X, Wang XP. Pharmacological and non-pharmacological treatments of sleep disorders in Parkinson’s disease. Curr Neuropharmacol. 2021;19(12):2233–2249. doi: 10.2174/1570159X19666210517115706
   PubMed Web of Science ®Google Scholar
• Wahbeh H, Elsas SM, Oken BS. Mind-body interventions: applications in neurology. Neurology. 2008 Jun 10;70(24):2321–2328. doi: 10.1212/01.wnl.0000314667.16386.5e
   PubMed Web of Science ®Google Scholar
• O’Regan D, Nesbitt A, Biabani N, et al. A novel group cognitive behavioral therapy approach to adult non-rapid eye movement parasomnias [brief research report]. Front Psychiatry. 2021 [2021-Jul-1];12:12.
   Web of Science ®Google Scholar
• Humbert M, Findley J, Hernandez-Con M, et al. Cognitive behavioral therapy for insomnia in Parkinson’s disease: a case series. NPJ Parkinsons Dis. 2017;3(1):25. doi: 10.1038/s41531-017-0027-z
   PubMedGoogle Scholar
• Osawa C, Kamei Y, Nozaki K, et al. Brief cognitive behavioral therapy for insomnia in Parkinson’s disease: a case series study 1. Jpn Psychol Res. 2021;63(2):59–71. doi: 10.1111/jpr.12287
   Web of Science ®Google Scholar
• Lebrun C, Gély-Nargeot MC, Bayard S. Insomnia comorbid to Parkinson’s disease part II: therapeutic approaches. Geriatr Psychol Neuropsychiatr Vieil. 2021 Apr 6. DOI:10.1684/pnv.2021.0927
   Web of Science ®Google Scholar
• Patel S, Ojo O, Genc G, et al. A computerized cognitive behavioral therapy randomized, controlled, pilot trial for insomnia in Parkinson disease (ACCORD-PD). J Clin Mov Disord. 2017;4(1):16. doi: 10.1186/s40734-017-0062-2
   PubMedGoogle Scholar
• Son HG, Choi E-O. The effects of mindfulness meditation-based complex exercise program on motor and nonmotor symptoms and quality of life in patients with Parkinson’s disease. Asian Nurs Res (Korean Soc Nurs Sci). 2018;12(2):145–153. doi: 10.1016/j.anr.2018.06.001
   Web of Science ®Google Scholar
• Wang K, Li K, Zhang P, et al. Mind-body exercises for non-motor symptoms of patients with Parkinson’s disease: a systematic review and meta-analysis. Front Aging Neurosci. 2021;13:770920. doi: 10.3389/fnagi.2021.770920
   PubMed Web of Science ®Google Scholar
• Elkins G, Sliwinski J, Bowers J, et al. Feasibility of clinical hypnosis for the treatment of Parkinson’s disease: a case study. Int J Clin Exp Hypn. 2013;61(2):172–182. doi: 10.1080/00207144.2013.753829
   PubMed Web of Science ®Google Scholar
• Amara AW, Chahine LM, Videnovic A. Treatment of sleep dysfunction in Parkinson’s disease. Curr Treat Options Neurol. 2017;19(7):1–16. doi: 10.1007/s11940-017-0461-6
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Titova N, Qamar MA, et al. The dashboard vitals of Parkinson’s: not to be missed yet an unmet need. J Pers Med. 2022 Dec 2;12(12):1994. doi: 10.3390/jpm12121994
   PubMed Web of Science ®Google Scholar